Last updated: 2023-05-29 FOR ILLUSTRATIVE PURPOSES - CODE SAMPLE

Follow-Up

Row

This week the field teams are visiting: Village 3/Village 4

Row

Follow-up diagnostic

63%

Follow-up diagnostic

71.5%

Follow-up diagnostic

71.5%

Follow-up diagnostic

68%

Follow-up diagnostic

65%

Follow-up diagnostic

58%

Row

Follow-up diagnostic

51%

Follow-up diagnostic

66%

Follow-up diagnostic

82%

Follow-up diagnostic

77%

Follow-up diagnostic

75%

Follow-up diagnostic

83%

Column

Follow-up rate summary by visit

Enrollment group Visit Participants surveyed Total enrolled Follow-up rate (%)
Bulal1
Bulal1 follow-up-01 104 179 59
Bulal1 follow-up-02 132 179 74
Bulal1 follow-up-03 103 179 58
Bulal1 follow-up-04 115 179 65
Bulal1 follow-up-05 93 179 52
Bulal1 follow-up-06 113 179 64
Bulal1 follow-up-07 133 179 75
Bulal1 follow-up-08 111 179 63
Bulal1 follow-up-09 107 179 60
Bulal1 follow-up-10 115 179 65
Bulal1 follow-up-11 82 179 46
Bulal2
Bulal2 follow-up-01 79 86 92
Bulal2 follow-up-02 65 86 76
Bulal2 follow-up-03 64 86 75
Bulal2 follow-up-04 66 86 77
Bulal2 follow-up-05 52 86 61
Bulal2 follow-up-06 65 86 76
Bulal2 follow-up-07 58 86 68
Bulal2 follow-up-08 51 86 60
Bulal2 follow-up-09 54 86 63
Bulal2 follow-up-10 36 86 42
Megiar1
Megiar1 Check 121 116 105
Megiar1 follow-up-01 93 116 81
Megiar1 follow-up-02 97 116 84
Megiar1 follow-up-03 88 116 76
Megiar1 follow-up-04 85 116 74
Megiar1 follow-up-05 80 116 69
Megiar1 follow-up-06 74 116 64
Megiar1 follow-up-07 86 116 75
Megiar1 follow-up-08 75 116 65
Megiar1 follow-up-09 79 116 69
Megiar1 follow-up-10 73 116 63
Megiar1 follow-up-11 75 116 65
Megiar1 follow-up-12 85 116 74
Megiar1 follow-up-13 74 116 64
Megiar2
Megiar2 Check 1 113 1
Megiar2 follow-up-01 98 113 87
Megiar2 follow-up-02 93 113 83
Megiar2 follow-up-03 91 113 81
Megiar2 follow-up-04 80 113 71
Megiar2 follow-up-05 61 113 54
Megiar2 follow-up-06 62 113 55
Megiar2 follow-up-07 82 113 73
Megiar2 follow-up-08 74 113 66
Megiar2 follow-up-09 76 113 68
Megiar2 follow-up-10 78 113 70
Megiar2 follow-up-11 71 113 63
Megiar2 follow-up-12 54 113 48
Megiar3
Megiar3 follow-up-01 18 20 90
Megiar3 follow-up-02 17 20 85
Megiar3 follow-up-03 9 20 45
Megiar3 follow-up-04 13 20 65
Megiar3 follow-up-05 16 20 80
Megiar3 follow-up-06 12 20 60
Megiar3 follow-up-07 13 20 65
Megiar3 follow-up-08 12 20 60
Megiar3 follow-up-09 15 20 75
Megiar3 follow-up-10 12 20 60
Megiar3 follow-up-11 10 20 50
Megiar4
Megiar4 follow-up-01 5 7 72
Megiar4 follow-up-02 6 7 86
Megiar4 follow-up-03 4 7 58
Megiar4 follow-up-04 4 7 58
Megiar4 follow-up-05 2 7 29
Megiar4 follow-up-06 5 7 72
Megiar4 follow-up-07 4 7 58
Megiar4 follow-up-08 6 7 86
Megiar4 follow-up-09 2 7 29
Megiar4 follow-up-10 3 7 43
Mirap1
Mirap1 follow-up-01 107 183 59
Mirap1 follow-up-02 118 183 65
Mirap1 follow-up-03 93 183 51
Mirap1 follow-up-04 69 183 38
Mirap1 follow-up-05 92 183 51
Mirap1 follow-up-06 92 183 51
Mirap1 follow-up-07 86 183 47
Mirap1 follow-up-08 93 183 51
Mirap1 follow-up-09 71 183 39
Mirap1 follow-up-10 99 183 55
Mirap1 follow-up-11 69 183 38
Mirap2
Mirap2 follow-up-01 54 76 72
Mirap2 follow-up-02 56 76 74
Mirap2 follow-up-03 53 76 70
Mirap2 follow-up-04 59 76 78
Mirap2 follow-up-05 59 76 78
Mirap2 follow-up-06 42 76 56
Mirap2 follow-up-07 50 76 66
Mirap2 follow-up-08 49 76 65
Mirap2 follow-up-09 46 76 61
Mirap2 follow-up-10 35 76 47
Mirap2 follow-up-11 3 76 4
Wasab1
Wasab1 Check 94 73 129
Wasab1 follow-up-01 71 73 98
Wasab1 follow-up-02 60 73 83
Wasab1 follow-up-03 61 73 84
Wasab1 follow-up-04 52 73 72
Wasab1 follow-up-05 51 73 70
Wasab1 follow-up-06 55 73 76
Wasab1 follow-up-07 59 73 81
Wasab1 follow-up-08 49 73 68
Wasab1 follow-up-09 63 73 87
Wasab1 follow-up-10 61 73 84
Wasab1 follow-up-11 56 73 77
Wasab1 follow-up-12 60 73 83
Wasab1 follow-up-13 50 73 69
Wasab2
Wasab2 follow-up-01 50 59 85
Wasab2 follow-up-02 46 59 78
Wasab2 follow-up-03 45 59 77
Wasab2 follow-up-04 36 59 62
Wasab2 follow-up-05 38 59 65
Wasab2 follow-up-06 48 59 82
Wasab2 follow-up-07 40 59 68
Wasab2 follow-up-08 48 59 82
Wasab2 follow-up-09 47 59 80
Wasab2 follow-up-10 45 59 77
Wasab2 follow-up-11 32 59 55
Wasab2 follow-up-12 41 59 70
Wasab3
Wasab3 follow-up-01 51 57 90
Wasab3 follow-up-02 52 57 92
Wasab3 follow-up-03 49 57 86
Wasab3 follow-up-04 43 57 76
Wasab3 follow-up-05 48 57 85
Wasab3 follow-up-06 40 57 71
Wasab3 follow-up-07 35 57 62
Wasab3 follow-up-08 39 57 69
Wasab3 follow-up-09 44 57 78
Wasab3 follow-up-10 42 57 74
Wasab3 follow-up-11 27 57 48
Wasab3 follow-up-12 3 57 6
Wasab4
Wasab4 follow-up-01 33 39 85
Wasab4 follow-up-02 32 39 83
Wasab4 follow-up-03 20 39 52
Wasab4 follow-up-04 36 39 93
Wasab4 follow-up-05 29 39 75
Wasab4 follow-up-06 36 39 93
Wasab4 follow-up-07 35 39 90
Wasab4 follow-up-08 31 39 80
Wasab4 follow-up-09 33 39 85
Wasab4 follow-up-10 32 39 83
Wasab4 follow-up-11 3 39 8

Median participant follow-up rate

Potential loss to follow-up (n=22)